-
Mashup Score: 27UM, AstraZeneca partner to boost lung cancer screenings - 1 month(s) ago
Big institutions in Maryland are joining forces to enhance community-based lung cancer screenings for those at high risk.
Source: www.wbaltv.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 23
Karen Warmkessel 410-328-8919 or (410) 404-1532 (cell) Kwarmkessel@umm.edu Deborah Kotz 410-706-4255 or 617-898-7955 (cell) dkotz@som.umaryland.edu
Source: www.medschool.umaryland.eduCategories: General Medicine News, Hem/OncsTweet-
Super excited to kick this partnership off to benefit all Marylanders. LDCT screening saves lives! https://t.co/Wm5HMpvuCZ @UMGCCC @UMMSFoundation @NCICRCHD @AstraZeneca @UMmedschool @AmericanCancer @NCICancerCtrl @theNCI @ASCO @lcrf_org @IASLC @marylandgov1 @chrisdraft @UPMC
-
-
Mashup Score: 2Sign the Petition - 10 month(s) ago
Eliminate ABIMs MOC requirement
Source: www.change.orgCategories: Latest Headlines, Oncologists1Tweet-
Eliminate ABIMs MOC requirement - Sign the Petition! https://t.co/A9yW2NEYJi via @Change
-
-
Mashup Score: 0The world’s platform for change - 1 year(s) ago
Change.org is the world’s largest petition platform, using technology to empower more than 200 million users to create the change they want to see.
Source: Change.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
@n8pennell Shame on #Cigna and those doctors. Should lose their medical license if true as such a behavior violates their oath and should be ground for whichever state board granted them license to withdraw it. This is beyond “I am just doing my job” https://t.co/AYrxDzMQiY
-
-
Mashup Score: 0Tarlatamab, a first-in-class DLL3-targeted bispecific T cell engager, in recurrent small-cell lung cancer: an open-label, phase 1 study - PubMed - 1 year(s) ago
In patients with heavily pretreated SCLC, tarlatamab demonstrated manageable safety with encouraging response durability. Further evaluation of this promising molecule is ongoing.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
Now out; a major step in the long road to a targeted therapy option for SCLC Tarlatamab, a first-in-class DLL3-targeted bispecific T cell engager, in recurrent small-cell lung cancer: an open-… https://t.co/5WpknPQcQV @UPMCHillmanCC @PittDeptofMed @AmgenOncology @PittHealthSci
-
-
Mashup Score: 0
Hydroxyurea and EPO in Sickle Cell Disease – Full Text View.
Source: clinicaltrials.govCategories: Hem/Oncs, Latest HeadlinesTweet-
Lagos university hospital, Nigeria for the site initiation visit for the ACHiEvE-SCD study for #sickle, a collaboration between @PittVMI and @LUTHofficial led by @JuliaXuMD, @TitiAdeyem0 @UPMCnews @chansteve73 @UPMCHillmanCC @EnricoNovelli @BIOVentures https://t.co/JZSPPszr5r https://t.co/OKoxp8c9Wo
-
-
Mashup Score: 0
#KeepDrJosieRolling I started this campaign for Josie, my wife of 22 … Stasa Tadic needs your support for Keep Dr Josie Rolling: Wheelchair Van, Bathroom
Source: gofundme.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Keep Dr Josie Rolling: Wheelchair Van, Bathroom https://t.co/YMFO1Kn7WO @UPMCHillmanCC @PittDeptofMed @UPMC @PittHealthSci @ASCO @ConquerCancerFd @steelers
-
-
Mashup Score: 0
#KeepDrJosieRolling I started this campaign for Josie, my wife of 22 … Stasa Tadic needs your support for Keep Dr Josie Rolling: Wheelchair Van, Bathroom
Source: gofundme.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Keep Dr Josie Rolling: Wheelchair Van, Bathroom https://t.co/WC8LoBfr0u
-
-
Mashup Score: 0Protect Patients from Delays to Care - 2 year(s) ago
Urge your lawmakers to support the Seniors’ Timely Access to Care Act
Source: asco.quorum.usCategories: Hem/Oncs, Latest HeadlinesTweet-
I asked my lawmakers to streamline prior authorization practices within the Medicare Advantage program. Join me! #ASCOAdvocacy https://t.co/MCny3nHn0H
-
-
Mashup Score: 1Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer - Full Text View - ClinicalTrials.gov - 2 year(s) ago
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer – Full Text View.
Source: clinicaltrials.govCategories: Hem/Oncs, Latest HeadlinesTweet-
A biomarker enriched targeted therapy trial of plk1 inhibitor onvansertib in relapsed small cell lung cancer now enrolling @UPMCHillmanCC. Thanks to @theNCI and @CardiffOncology for funding/drug @UPMC @UPMCnews @PittHealthSci @PittDeptofMed ✔️details at https://t.co/P6qwfrONEM
-
AZ and @UMGCCC form new partnership to improve LDCT screening across Maryland. Committed partners = Great impact. @umms @UMmedschool @UMBaltimore @IASLC @lcrf_org @NCICRCHD @theNCI https://t.co/yCVyGTE9cl